Cargando…

Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection

SIMPLE SUMMARY: BCLC-B HCC encompasses heterogeneous populations with varied tumor burden and liver reserve resulting in diverse clinical outcomes to TACE. Liver function deterioration would happen after TACE in patients with high tumor burden. Here, we found that the risk of post-TACE acute ALBI-gr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Chen-Ta, Lee, I-Cheng, Lee, Rheun-Chuan, Hung, Ya-Wen, Su, Chien-Wei, Hou, Ming-Chih, Chao, Yee, Huang, Yi-Hsiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431519/ https://www.ncbi.nlm.nih.gov/pubmed/34503135 http://dx.doi.org/10.3390/cancers13174325

Ejemplares similares

Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Ho, Shu-Yein, et al.
Publicado: (2023)

Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization
por: Lee, Hsin-Lun, et al.
Publicado: (2019)

To determine the prognostic value of the albumin–bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Khalid, Muhammad Ali, et al.
Publicado: (2019)

Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade
por: Liao, Jia-I, et al.
Publicado: (2023)

Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Ho, Shu-Yein, et al.
Publicado: (2017)

Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma
por: Wei, Cheng-Yi, et al.
Publicado: (2020)

The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan
por: Tseng, Chi-Lung, et al.
Publicado: (2015)

Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria
por: Saito, Natsuhiko, et al.
Publicado: (2023)

Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization
por: Ananchuensook, Prooksa, et al.
Publicado: (2022)

Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery
por: Cho, Wei-Ru, et al.
Publicado: (2020)

Superselective Transarterial Chemoembolization for Unresectable or “Ablation Unsuitable” Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study
por: Yan, Liangliang, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization
por: Wu, Yanfang, et al.
Publicado: (2022)

Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score
por: Ho, Shu-Yein, et al.
Publicado: (2022)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
por: Zhou, Qunfang, et al.
Publicado: (2020)

Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma
por: Roth, Gael S., et al.
Publicado: (2022)

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
por: Kim, Jun Young, et al.
Publicado: (2016)

Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
por: Chen, Lei, et al.
Publicado: (2020)

Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score
por: Ho, Shu-Yein, et al.
Publicado: (2023)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
por: Chen, Shuling, et al.
Publicado: (2019)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma
por: Kaibori, Masaki, et al.
Publicado: (2021)

Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
por: Lim, Ji Young, et al.
Publicado: (2020)

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
por: Kudo, Masatoshi, et al.
Publicado: (2023)

Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate‐stage hepatocellular carcinoma undergoing chemoembolization
por: Bannangkoon, Kittipitch, et al.
Publicado: (2023)

A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Ogasawara, Sadahisa, et al.
Publicado: (2015)

Latent Class Analysis of Subphenotypes in Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Chen, Siyu, et al.
Publicado: (2022)

Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation
por: Lei, Jianyong, et al.
Publicado: (2017)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study
por: Jin, Zhicheng, et al.
Publicado: (2021)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization
por: Lee, Ji Eun, et al.
Publicado: (2020)

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
por: Baur, Johannes, et al.
Publicado: (2016)

Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma
por: Liu, Furong, et al.
Publicado: (2019)

Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
por: Lu, Linbin, et al.
Publicado: (2021)

Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer
por: Pocha, Pauline Viviane, et al.
Publicado: (2021)

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
por: Hatanaka, Takeshi, et al.
Publicado: (2023)

Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization
por: Xu, Jiachen, et al.
Publicado: (2023)

Investigating Up-to-Seven Criteria and APRI (AST Platelet Ratio) as Prognostic Factors in Intermediate-Stage Hepatocellular Carcinoma Patients Who Received Transarterial Chemoembolization
por: Inmutto, Nakarin, et al.
Publicado: (2022)

Child Pugh and ALBI grade: past, present or future?
por: Rimini, Margherita, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fkcubrab6am5lkqvo0br2isg3t